Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 12 January 2018


Synjardy is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise:
- in patients insufficiently controlled on their maximally tolerated dose of metformin alone
- in combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with metformin and these medicinal products
- in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the population studied, see sections 4.4, 4.5 and 5.1.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.



Learn about the complex factors influencing development of obesity.

+ 4 more

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003770
Orphan designation No
Date First Approved 27-05-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Boehringer Ingelheim GmbH
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions